CONTEXT: The relationship between sex steroids and fracture is poorly understood. OBJECTIVE: The objective of the study was to examine associations between nonvertebral fracture risk and bioavailable estradiol (bioE2), bioavailable testosterone (bioT), and SHBG. DESIGN: This was a case-cohort study. SETTING: The Osteoporotic Fractures in Men Study (MrOS) was conducted in a prospective U.S. cohort in 5995 community-dwelling men 65 yr old or older. PARTICIPANTS: Participants included a subcohort of 1436 randomly chosen white men plus all 446 minorities and all those with incident hip and other nonvertebral fractures. MAIN OUTCOME MEASURES: Baseline testosterone and estradiol were measured by mass spectrometry (MS) and SHBG by RIA. RESULTS: Men with the lowest bioE2 (<11.4 pg/ml) or highest SHBG (>59.1 nm) had greater risk of all nonvertebral fractures [adjusted hazard ratio (HR) [95% confidence interval]: 1.5 (1.2-1.9) and 1.4 (1.1-21.8), respectively]. Men with the lowest bioT (<163.5 ng/dl) had no increased fracture risk after adjustment for bioE2 [adjusted HR 1.16 (0.90-1.49)]. A significant interaction between SHBG and bioT (P = 0.03) resulted in men with low bioT and high SHBG having higher fracture risk [HR 2.1 (1.4-3.2)]. Men with low bioE2, low bioT, and high SHBG were at highest risk [HR 3.4 (2.2-5.3)]. CONCLUSIONS: Older men with low bioE2 or high SHBG levels are at increased risk of nonvertebral fracture. When SHBG levels are high, men with low bioT levels have higher risk. The strongest association occurred when all measures were considered in combination.
CONTEXT: The relationship between sex steroids and fracture is poorly understood. OBJECTIVE: The objective of the study was to examine associations between nonvertebral fracture risk and bioavailable estradiol (bioE2), bioavailable testosterone (bioT), and SHBG. DESIGN: This was a case-cohort study. SETTING: The Osteoporotic Fractures in Men Study (MrOS) was conducted in a prospective U.S. cohort in 5995 community-dwelling men 65 yr old or older. PARTICIPANTS: Participants included a subcohort of 1436 randomly chosen white men plus all 446 minorities and all those with incident hip and other nonvertebral fractures. MAIN OUTCOME MEASURES: Baseline testosterone and estradiol were measured by mass spectrometry (MS) and SHBG by RIA. RESULTS:Men with the lowest bioE2 (<11.4 pg/ml) or highest SHBG (>59.1 nm) had greater risk of all nonvertebral fractures [adjusted hazard ratio (HR) [95% confidence interval]: 1.5 (1.2-1.9) and 1.4 (1.1-21.8), respectively]. Men with the lowest bioT (<163.5 ng/dl) had no increased fracture risk after adjustment for bioE2 [adjusted HR 1.16 (0.90-1.49)]. A significant interaction between SHBG and bioT (P = 0.03) resulted in men with low bioT and high SHBG having higher fracture risk [HR 2.1 (1.4-3.2)]. Men with low bioE2, low bioT, and high SHBG were at highest risk [HR 3.4 (2.2-5.3)]. CONCLUSIONS: Older men with low bioE2 or high SHBG levels are at increased risk of nonvertebral fracture. When SHBG levels are high, men with low bioT levels have higher risk. The strongest association occurred when all measures were considered in combination.
Authors: E Barrett-Connor; J E Mueller; D G von Mühlen; G A Laughlin; D L Schneider; D J Sartoris Journal: J Clin Endocrinol Metab Date: 2000-01 Impact factor: 5.958
Authors: Scott D Moffat; Alan B Zonderman; E Jeffrey Metter; Marc R Blackman; S Mitchell Harman; Susan M Resnick Journal: J Clin Endocrinol Metab Date: 2002-11 Impact factor: 5.958
Authors: P Szulc; F Munoz; B Claustrat; P Garnero; F Marchand; F Duboeuf; P D Delmas Journal: J Clin Endocrinol Metab Date: 2001-01 Impact factor: 5.958
Authors: E Legrand; C Hedde; Y Gallois; I Degasne; F Boux de Casson; E Mathieu; M F Baslé; D Chappard; M Audran Journal: Bone Date: 2001-07 Impact factor: 4.398
Authors: T J Beck; T L Oreskovic; K L Stone; C B Ruff; K Ensrud; M C Nevitt; H K Genant; S R Cummings Journal: J Bone Miner Res Date: 2001-06 Impact factor: 6.741
Authors: S Amin; Y Zhang; C T Sawin; S R Evans; M T Hannan; D P Kiel; P W Wilson; D T Felson Journal: Ann Intern Med Date: 2000-12-19 Impact factor: 25.391
Authors: Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen Journal: Endocr Rev Date: 2012-03-20 Impact factor: 19.871
Authors: Elizabeth Barrett-Connor; Gail A Laughlin; Hong Li; Carrie M Nielson; P Ying Wang; Tien T Dam; Jane A Cauley; Kristine E Ensrud; Marcia L Stefanick; Edith Lau; Andrew R Hoffman; Eric S Orwoll Journal: J Bone Miner Res Date: 2012-11 Impact factor: 6.741
Authors: Chevon M Rariy; Sarah J Ratcliffe; Rachel Weinstein; Shalender Bhasin; Marc R Blackman; Jane A Cauley; John Robbins; Joseph M Zmuda; Tamara B Harris; Anne R Cappola Journal: J Clin Endocrinol Metab Date: 2011-02-02 Impact factor: 5.958
Authors: Johannes D Veldhuis; Olga P Bondar; Roy B Dyer; Sergey A Trushin; Eric W Klee; Ravinder J Singh; George G Klee Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: A S Cheung; S Baqar; R Sia; R Hoermann; S Iuliano-Burns; T D T Vu; C Chiang; E J Hamilton; E Gianatti; E Seeman; J D Zajac; M Grossmann Journal: Osteoporos Int Date: 2014-05-07 Impact factor: 4.507
Authors: Eric S Orwoll; Jodi Lapidus; Patty Y Wang; Liesbeth Vandenput; Andrew Hoffman; Howard A Fink; Gail A Laughlin; Maria Nethander; Östen Ljunggren; Andreas Kindmark; Mattias Lorentzon; Magnus K Karlsson; Dan Mellström; Anthony Kwok; Sundeep Khosla; Timothy Kwok; Claes Ohlsson Journal: J Bone Miner Res Date: 2016-11-14 Impact factor: 6.741
Authors: Anna E Börjesson; Helen H Farman; Cecilia Engdahl; Antti Koskela; Klara Sjögren; Jenny M Kindblom; Alexandra Stubelius; Ulrika Islander; Hans Carlsten; Maria Cristina Antal; Andrée Krust; Pierre Chambon; Juha Tuukkanen; Marie K Lagerquist; Sara H Windahl; Claes Ohlsson Journal: J Bone Miner Res Date: 2013-05 Impact factor: 6.741
Authors: William A Bauman; Mark A Korsten; Miroslav Radulovic; Gregory J Schilero; Jill M Wecht; Ann M Spungen Journal: Top Spinal Cord Inj Rehabil Date: 2012